MetaVia (MTVA) Expected to Post Quarterly Earnings on Thursday

Posted by Renee Jackson on Jul 30th, 2026

MetaVia (NASDAQ:MTVA – Get Free Report) is projected to announce its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($0.85) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, August 7, 2026 at 9:30 AM ET.

MetaVia (NASDAQ:MTVA – Get Free Report) last issued its earnings results on Thursday, May 14th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.03). On average, analysts expect MetaVia to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

MetaVia Stock Up 0.7%

NASDAQ MTVA opened at $1.44 on Thursday. MetaVia has a 52 week low of $0.97 and a 52 week high of $19.03. The business’s fifty day simple moving average is $1.97 and its 200-day simple moving average is $1.94. The firm has a market cap of $7.43 million, a PE ratio of -0.28 and a beta of 0.97.

Wall Street Analyst Weigh In

MTVA has been the subject of a number of analyst reports. Wall Street Zen raised shares of MetaVia to a “sell” rating in a report on Saturday, June 20th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MetaVia in a research note on Tuesday, July 21st. Finally, HC Wainwright reiterated a “buy” rating on shares of MetaVia in a report on Friday, July 10th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $20.00.

Read Our Latest Report on MetaVia

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in MetaVia stock. Virtu Financial LLC bought a new position in shares of MetaVia Inc. (NASDAQ:MTVA – Free Report) during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned 0.14% of MetaVia as of its most recent SEC filing. Institutional investors own 1.37% of the company’s stock.

About MetaVia

(Get Free Report)

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.